Immucell (ICCC) Consolidated Net Income (2016 - 2025)
Immucell (ICCC) has disclosed Consolidated Net Income for 16 consecutive years, with -$139749.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Consolidated Net Income rose 80.08% year-over-year to -$139749.0, compared with a TTM value of $2.3 million through Sep 2025, up 160.97%, and an annual FY2024 reading of -$2.2 million, up 62.65% over the prior year.
- Consolidated Net Income was -$139749.0 for Q3 2025 at Immucell, down from $501881.0 in the prior quarter.
- Across five years, Consolidated Net Income topped out at $1.4 million in Q1 2025 and bottomed at -$2.3 million in Q1 2023.
- Average Consolidated Net Income over 5 years is -$457589.9, with a median of -$441303.0 recorded in 2021.
- The sharpest move saw Consolidated Net Income crashed 2349.8% in 2022, then skyrocketed 430.46% in 2025.
- Year by year, Consolidated Net Income stood at $74134.0 in 2021, then plummeted by 2349.8% to -$1.7 million in 2022, then surged by 31.66% to -$1.1 million in 2023, then skyrocketed by 145.14% to $514555.0 in 2024, then plummeted by 127.16% to -$139749.0 in 2025.
- Business Quant data shows Consolidated Net Income for ICCC at -$139749.0 in Q3 2025, $501881.0 in Q2 2025, and $1.4 million in Q1 2025.